Accueil   Diary - News   All news Success of Theranexus' IPO on Euronext Growth in Paris

Success of Theranexus’ IPO on Euronext Growth in Paris

Lyon, 25 October 2017 – Theranexus, an innovative biopharmaceutical company that focuses on the treatment of diseases of the central nervous system, announced today the success of its initial public offering (IPO) and the upcoming listing of its shares for trading on the Euronext Growth market in Paris (FR0013286259 - ALTHX).

 

The IPO, carried out in connection with an open price offering (OPO) and a global placement offering (Global Placement Offering), will enable the Company to raise approximately €19.6 million through a capital increase (after fully exercising the extension clause (Extension Clause)). This amount could be increased to approximately €21.0 million if the over-allotment option is fully exercised (Over-allotment Option).

 

Franck Mouthon, Chairman and Chief Executive Officer of Theranexus, said: "We would like to truly thank our institutional and retail investors who have placed their trust in us during the initial public offering. We express our gratitude particularly to our long-standing shareholders who have reaffirmed their support, by fully taking part in our ambitious growth strategy. With this round of capital raising, we are going to actively continue to deploy and develop our platform and our portfolio of drug candidates. "

 

 

 

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree